Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma (R-GO)

This study has been terminated.
(The predefined termination criterion of more than 10 patients without CR or PR was matched.)
Information provided by (Responsible Party):
Martin Hoffmann, German Low Grade Lymphoma Study Group Identifier:
First received: August 4, 2009
Last updated: March 13, 2012
Last verified: March 2012

The purpose of the phase I part is to determine the tolerability, the initial safety profile and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent lymphoma.

Condition Intervention Phase
Indolent Lymphoma
Drug: Therapy with Rituximab, Gemcitabine and Oxaliplatin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma

Resource links provided by NLM:

Further study details as provided by German Low Grade Lymphoma Study Group:

Primary Outcome Measures:
  • Overall Remission Rate [ Time Frame: end of therapy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression Free Survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Median Overall Survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Toxicity [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Enrollment: 56
Study Start Date: January 2003
Estimated Study Completion Date: June 2012
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Therapy with Rituximab, Gemcitabine and Oxaliplatin
    Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day Tag 29 for 4 cycles
    Other Names:
    • Rituximab = Mabthera, Rituxan
    • Gemcitabine = Gemzar
    • Oxaliplatin = Eloxatin

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Need for therapy in patients with relapsed/refractory patients
  • Histological proven diagnosis of an indolent B-cell lymphoma according to the World Health Organization (WHO) classification belonging to one of the following entities:

    • follicular lymphoma
    • mantle cell lymphoma
    • lymphoplasmacytic lymphoma
    • nodal or splenic marginal zone lymphoma
    • measurable disease
    • lymphoma specific therapy in the last four weeks
    • WHO performance grade 0, 1 or 2

Exclusion Criteria

  • Patients suitable for high dose therapy
  • Transformation in high grade lymphoma
  • Leukocytes < 1,5/nl or platelets < 100/nl (except due to lymphoma)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00954005

Klinikum Ludwigshafen
Ludwigshafen, Germany, 67063
Sponsors and Collaborators
German Low Grade Lymphoma Study Group
Principal Investigator: Martin Hoffmann, Dr. German Low Grade Lymphoma Study Group
  More Information

Additional Information:
No publications provided

Responsible Party: Martin Hoffmann, Dr. Martin Hoffmann, Klinikum Ludwigshafen, German Low Grade Lymphoma Study Group Identifier: NCT00954005     History of Changes
Other Study ID Numbers: 001
Study First Received: August 4, 2009
Last Updated: March 13, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by German Low Grade Lymphoma Study Group:
relapsed indolent lymphoma

Additional relevant MeSH terms:
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on November 24, 2014